- ISIN
- US15678C1027
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Oct 11, 2024
Highlights
- Market Cap
- $671.21M
- Enterprise Value
- $649.21M
- EPS (TTM)
- -$1.62
- Total Revenue (TTM)
- $95.07M
- Gross Profit (TTM)
- $83.39M
- EBITDA (TTM)
- -$59.25M
- Year Range
- $10.85 - $24.33
- Target Price
- $30.00
- ROA (TTM)
- -33.90%
- ROE (TTM)
- -42.87%
- Avg. Volume (1M)
- 361K
- Avg. Volume Value (1M)
- $6.67M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CBLL Performance Chart
CeriBell, Inc (CBLL) is down 19.3% since the beginning of the year. At $18 per share, CBLL is trading 27.3% below its 52-week high of $24.
Loading charts...
Compare this symbol against anything
Returns By Period
CeriBell, Inc (CBLL) has returned -19.33% so far this year and 25.11% over the past 12 months.
CeriBell, Inc
- 1D
- 0.28%
- 1M
- -9.51%
- 6M
- -14.17%
- YTD
- -19.33%
- 1Y
- 25.11%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -14.10%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
CBLL Monthly Returns History
Based on dividend-adjusted daily data since Oct 11, 2024, CBLL's average daily return is +0.04%, while the average monthly return is -0.06%.
Historically, 41% of months were positive and 59% were negative. The best month was Nov 2025 with a return of +48.9%, while the worst month was Jul 2025 at -23.1%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 4 months.
On a daily basis, CBLL closed higher 47% of trading days. The best single day was Apr 11, 2025 with a return of +34.5%, while the worst single day was Apr 10, 2025 at -42.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.02% | -9.41% | -1.82% | 9.98% | -8.48% | 5.42% | -9.05% | -19.33% | |||||
| 2025 | -11.09% | 1.00% | -17.34% | -16.24% | 4.47% | 11.42% | -23.12% | -17.85% | -2.87% | -0.78% | 48.86% | 29.23% | -15.26% |
| 2024 | 13.03% | 9.51% | -10.11% | 11.26% |
Benchmark Metrics
CeriBell, Inc has an annualized alpha of -13.56%, beta of 1.48, and R2 of 0.13 versus S&P 500 Index. Calculated based on daily prices since October 11, 2024.
- This stock participated in 123.06% of S&P 500 Index downside but only -5.00% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.13 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -13.56%
- Beta
- 1.48
- R²
- 0.13
- Upside Capture
- -5.00%
- Downside Capture
- 123.06%
Return for Risk
Risk / Return Rank
CBLL ranks 59 for risk / return — above 59% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for CeriBell, Inc (CBLL) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CBLL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.00 | ||
| Sortino ratioReturn per unit of downside risk | -1.04 | ||
| Omega ratioGain probability vs. loss probability | 1.12 | 1.25 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | 0.75 | 2.00 | -1.25 |
| Martin ratioReturn relative to average drawdown | 1.27 | 8.49 | -7.22 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the CeriBell, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the CeriBell, Inc was 63.89%, occurring on Nov 4, 2025. The portfolio has not yet recovered.
The current CeriBell, Inc drawdown is 41.50%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-63.89%Nov 2025 | 11mo | — | 1y 7moDec 2024 - now | — |
-13.64%Nov 2024 | 10d | 15d | 25dNov 2024 - Dec 2024 | — |
-4.04%Dec 2024 | 1d | 1d | 2dDec 2024 - Dec 2024 | — |
-4.03%Oct 2024 | 6d | 9d | 15dOct 2024 - Nov 2024 | — |
Drawdown Indicators
| CBLL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.89% | -56.78% | -7.11% |
Max Drawdown (1Y)Largest decline over 1 year | -30.52% | -9.10% | -21.42% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -41.50% | -1.58% | -39.92% |
Average DrawdownAverage peak-to-trough decline | -36.42% | -10.70% | -25.72% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.03% | 2.14% | +15.89% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of CeriBell, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how CeriBell, Inc is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CBLL relative to other companies in the Medical Devices industry. Currently, CBLL has a P/S ratio of 6.9. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CBLL in comparison with other companies in the Medical Devices industry. Currently, CBLL has a P/B value of 4.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CBLL
Add CeriBell, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CBLL